Gynecologic Cancer News

It’s not often that a 2 a.m. phone call marks the highlight of someone’s career.

The FDA announced several regulatory actions the past few weeks.

Linda H. Malkas, PhD, remembers the day a photograph for a newspaper changed her life.

Cancer drugs that received approval based on increased OS compared with other measures had the lowest median annual cost, according to a research letter published in JAMA Internal Medicine.

A triple-therapy combination extended OS compared with historical data among certain patients with advanced HPV-positive cancers, according to one of the agent’s manufacturers.

Several novel treatment regimens for gynecologic cancer emerged during the past year.

Genomic testing continues to provide oncologists with a wealth of meaningful, treatment-guiding information for a growing number of cancers.

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

Despite decreases in cervical cancer screenings between 1999 and 2019 among older women with Medicare fee-for-service coverage, this group may be overspending on screening-related services, according to data in JAMA Internal Medicine.

A combination of dostarlimab-gxly and standard-of-care chemotherapy significantly extended PFS compared with placebo and chemotherapy among women with primary advanced or recurrent endometrial cancer, topline data showed.